🔎 Trials Near Me

Home › Prostate Cancer › NCT04420702

Diffusion Basis Spectrum Imaging of the Prostate

Recruiting

Diffusion Basis Spectrum Imaging of the Prostate: A Virtual Biopsy to Accurately Diagnose Prostate Cancer

Who can join

Ages 18 and older · Men

Full eligibility criteria
Inclusion Criteria:

* Over 18 years of age and willing and able to provide informed consent.
* Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
* Including those men with:

  * an elevated PSA and no prior biopsy
  * an elevated PSA and a negative prior biopsy
* Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion Criteria:

* Patients with any clinical contraindication to MRI

  \*Including but not limited to:
  * Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
  * Those with cochlear implants
  * Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
  * Those who cannot lie flat for over 1 hour
* Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)

About the study

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

What is being tested

Sponsor: Washington University School of Medicine · Participants: 500 · Started: Feb 27, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04420702

Locations in the U.S.

MissouriWashington University School of Medicine, St Louis

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.